Increased levels of glucocorticoid receptor (GR) expression in AIDS-Kaposi's sarcoma (KS) (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Increased levels of glucocorticoid receptor (GR) expression in AIDS-Kaposi's sarcoma (KS) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A3016 1993. Unique Identifier : AIDSLINE ICDB/93693961
Guo W; Antakly T; Cadotte M; Masood R; Kunkel L; Jung B; Brynes R; Gill P; Dept. of Pathology, Univ. of Montreal, H3C 3J7, Canada

Abstract: Development and progression of Kaposi's sarcoma after institution of glucocorticoid therapy has been reported in patients (pts) with HIV infection and in renal transplant recipients. We examined the localization and level of GR in 'normals' and in 25 pts with HIV using sensitive immunocytochemistry and RIA procedures (Antakly, Cancer Res, 1989; ibid Endo, 1990). GR mRNA levels were monitored by PCR. All tumors express high levels of GR which was demonstrated in 'spindle cells' as well as endothelial and epidermal cells. The cytoplasm as well as nucleus contain the GR. As compared with normal heterosexual men and women without HIV, KS tissues contain more than twice the GR level of normal skin. Also, GR levels of the KS lesion were significantly higher than uninvolved skin from the same individuals. Next, we studied whether several cytokines that regulate KS cell growth also upregulate cellular GR levels. Oncostatin M, IL6 and TNF alpha resulted in an upregulation of GR expression. These data thus demonstrate the localization and difference in GR expression between 'normal' and KS tissues and show that growth promotion by cytokines may be potentiated by an induction of cellular GR.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*METABOLISM/ PATHOLOGY Cell Division/DRUG EFFECTS Female Homosexuality Human Interleukin-6/PHARMACOLOGY Male Peptides/PHARMACOLOGY Receptors, Glucocorticoid/GENETICS/*METABOLISM RNA, Messenger/METABOLISM Sarcoma, Kaposi's/ETIOLOGY/*METABOLISM/PATHOLOGY Skin Neoplasms/ETIOLOGY/*METABOLISM/PATHOLOGY Tumor Necrosis Factor/PHARMACOLOGY Up-Regulation (Physiology)/DRUG EFFECTS ABSTRACT
930830
M9380826

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .